{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:31:47Z","timestamp":1785929507916,"version":"3.56.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bbrep.2024.101913","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T02:44:30Z","timestamp":1736045070000},"page":"101913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Elucidating the therapeutic potential of indazole derivative bindarit against K-ras receptor: An in-silico analysis using molecular dynamics exploration"],"prefix":"10.1016","volume":"41","author":[{"given":"Parmar Keshri","family":"Nandan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6722-1658","authenticated-orcid":false,"given":"Jayanthi","family":"Sivaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrep.2024.101913_bib1","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1073\/pnas.1812963116","article-title":"Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS\u2013SOS1 interaction","volume":"116","author":"Hillig","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbrep.2024.101913_bib2","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1073\/pnas.1116510109","article-title":"Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity","volume":"109","author":"Maurer","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbrep.2024.101913_bib3","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1126\/science.1062023","article-title":"The guanine nucleotide-binding switch in three dimensions","volume":"294","author":"Vetter","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bbrep.2024.101913_bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrc2109","article-title":"Hyperactive Ras in developmental disorders and cancer","volume":"74 7","author":"Schubbert","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrep.2024.101913_bib5","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1242\/jcs.182873","article-title":"RAS isoforms and mutations in cancer at a glance","volume":"129","author":"Hobbs","year":"2016","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbrep.2024.101913_bib6","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1242\/jcs.182873","article-title":"RAS isoforms and mutations in cancer at a glance","volume":"129","author":"Hobbs","year":"2016","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.bbrep.2024.101913_bib7","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/1541-7786.MCR-15-0203","article-title":"Biochemical and structural analysis of common cancer-associated KRAS mutations","volume":"13","author":"Hunter","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bbrep.2024.101913_bib8","first-page":"1","article-title":"Oncogenic G12D mutation alters local conformations and dynamics of K-Ras","volume":"91 9","author":"Vatansever","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrep.2024.101913_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1126\/science.277.5324.333","article-title":"The ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants","volume":"277","author":"Scheffzek","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bbrep.2024.101913_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: the first 30 years","volume":"36 3","author":"Malumbres","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrep.2024.101913_bib11","doi-asserted-by":"crossref","first-page":"E157","DOI":"10.1038\/ctg.2016.18","article-title":"KRAS G12D mutation subtype is a prognostic factor for advanced pancreatic adenocarcinoma","volume":"7","author":"Bournet","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.bbrep.2024.101913_bib12","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1200\/JCO.2020.38.15_suppl.4641","article-title":"Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): clinical\/molecular correlations and real-world outcomes across standard therapies","volume":"38","author":"Hendifar","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrep.2024.101913_bib13","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-21-3581","article-title":"Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma","volume":"28","author":"Philip","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrep.2024.101913_bib14","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRASG12DInhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrep.2024.101913_bib15","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","article-title":"FDA approval summary: Sotorasib for KRAS G12C mutated metastatic NSCLC","volume":"28","author":"Nakajima","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrep.2024.101913_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2021.115648","article-title":"A novel indazole derivative, compound Cyy-272, attenuates LPS-induced acute lung injury by inhibiting JNK phosphorylation","volume":"428","author":"Liu","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bbrep.2024.101913_bib17","article-title":"In vivo and in vitro anti-inflammatory activity of indazole and its derivatives","volume":"10","author":"Cheekavolu","year":"2016","journal-title":"J. Clin. Diagn. Res."},{"key":"10.1016\/j.bbrep.2024.101913_bib18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jcph.73","article-title":"Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis","volume":"53","author":"Rini","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bbrep.2024.101913_bib19","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.18632\/oncotarget.13753","article-title":"Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrep.2024.101913_bib20","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00435.2004","article-title":"Treatment with bindarit, a blocker of MCP-1 synthesis, protects mice against acute pancreatitis","volume":"288","author":"Bhatia","year":"2005","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.bbrep.2024.101913_bib21","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1046\/j.1523-1755.1998.00804.x","article-title":"Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease","volume":"53","author":"Zoja","year":"1998","journal-title":"Kidney Int."},{"key":"10.1016\/j.bbrep.2024.101913_bib22","doi-asserted-by":"crossref","first-page":"e1385","DOI":"10.4244\/EIJY15M12_03","article-title":"A double-blind randomised study to evaluate the efficacy and safety of bindarit in preventing coronary stent restenosis","volume":"12","author":"Colombo","year":"2016","journal-title":"EuroIntervention"},{"key":"10.1016\/j.bbrep.2024.101913_bib23","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10585-012-9473-5","article-title":"Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models","volume":"29","author":"Zollo","year":"2012","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.bbrep.2024.101913_bib24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cyto.2013.12.011","article-title":"Effects of the MCP-1 synthesis inhibitor bindarit on tumorigenesis and inflammatory markers in the C3(1)\/SV40Tag mouse model of breast cancer","volume":"66","author":"Steiner","year":"2014","journal-title":"Cytokine"},{"key":"10.1016\/j.bbrep.2024.101913_bib25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bbrep.2024.101913_bib26","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1107\/S090744490200985X","article-title":"PDB Goodies\u2013 a web-based GUI to manipulate the protein Data Bank file","volume":"58","author":"Hussain","year":"2002","journal-title":"Acta Crystallogr. D"},{"key":"10.1016\/j.bbrep.2024.101913_bib27","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/elps.1150181505","article-title":"SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling","volume":"18","author":"Guex","year":"1997","journal-title":"Electrophoresis"},{"key":"10.1016\/j.bbrep.2024.101913_bib28","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bbrep.2024.101913_bib29","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00249-011-0700-9","article-title":"Definition and testing of the GROMOS force-field versions 54A7 and 54B7","volume":"40","author":"Schmid","year":"2011","journal-title":"Eur. Biophys. J."},{"key":"10.1016\/j.bbrep.2024.101913_bib30","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1021\/ct100747y","article-title":"Validation of the GROMOS 54A7 force field with respect to \u03b2-peptide folding","volume":"7","author":"Huang","year":"2011","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.bbrep.2024.101913_bib31","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1021\/ct200196m","article-title":"An automated force field topology builder (ATB) and repository: version 1.0","volume":"7","author":"Malde","year":"2011","journal-title":"J. Chem. Theor. Comput."},{"key":"10.1016\/j.bbrep.2024.101913_bib32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/bab.1957","article-title":"Computational investigations on the dynamic binding effect of molecular tweezer CLR01 toward intrinsically disordered HIV-1 Nef","volume":"68","author":"Bhattarai","year":"2021","journal-title":"Biotechnol. Appl. Biochem."},{"key":"10.1016\/j.bbrep.2024.101913_bib33","article-title":"Computational investigation of phytochemicals identified from medicinal plant extracts against tuberculosis","author":"Ponnusamy","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrep.2024.101913_bib34","doi-asserted-by":"crossref","first-page":"226","DOI":"10.4103\/1735-5362.288425","article-title":"Discovery of direct inhibitor of KRAS oncogenic protein by natural products: a combination of pharmacophore search, molecular docking, and molecular dynamic studies","volume":"15","author":"Hashemi","year":"2020","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.bbrep.2024.101913_bib35","doi-asserted-by":"crossref","DOI":"10.1080\/07391102.2023.2174596","article-title":"Investigating the binding affinity of andrographolide against human SARS-CoV-2 spike receptor-binding domain through docking and molecular dynamics simulations","volume":"41","author":"Bhattarai","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbrep.2024.101913_bib36","first-page":"19","article-title":"XMGRACE, version 5.1. 19, cent. Coast. Land-margin res. Oregon grad. Inst","volume":"OR 2","author":"Turner","year":"2005","journal-title":"Sci. Technol. Beaverton"},{"issue":"6","key":"10.1016\/j.bbrep.2024.101913_bib37","first-page":"1","article-title":"Structural insights into conformational stability of both wild-type and mutant EZH2 receptor","volume":"61","author":"Aier","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrep.2024.101913_bib38","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077453","article-title":"Molecular dynamic simulation reveals damaging impact of RAC1 F28L mutation in the switch I region","volume":"8","author":"Kumar","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrep.2024.101913_bib39","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0959-440X(00)00061-0","article-title":"Collective protein dynamics in relation to function","volume":"10","author":"Berendsen","year":"2000","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bbrep.2024.101913_bib40","doi-asserted-by":"crossref","first-page":"6516","DOI":"10.1021\/acs.chemrev.5b00562","article-title":"Protein ensembles: how does nature harness thermodynamic fluctuations for life? The diverse functional roles of conformational ensembles in the cell","volume":"116","author":"Wei","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bbrep.2024.101913_bib41","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1021\/acscentsci.8b00274","article-title":"Quantifying the intrinsic conformation energy landscape topography of proteins with large-scale open-closed transition","volume":"4","author":"Chu","year":"2018","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.bbrep.2024.101913_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrep.2024.101913_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbrep.2024.101913_bib44","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrep.2024.101913_bib45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1021\/cc9800071","article-title":"A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases","volume":"1","author":"Ghose","year":"1999","journal-title":"J. Comb. Chem."},{"key":"10.1016\/j.bbrep.2024.101913_bib46","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1021\/jm015507e","article-title":"Simple selection criteria for drug-like chemical matter","volume":"44","author":"Muegge","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrep.2024.101913_bib47","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1021\/jm000292e","article-title":"Prediction of drug absorption using multivariate statistics","volume":"43","author":"Egan","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrep.2024.101913_bib48","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/1062936X.2023.2261842","article-title":"Assessing structural insights into in-house arylsulfonyl L-(+) glutamine MMP-2 inhibitors as promising anticancer agents through structure-based computational modelling approaches","volume":"34","author":"Baidya","year":"2023","journal-title":"SAR QSAR Environ. Res."},{"key":"10.1016\/j.bbrep.2024.101913_bib49","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.sjbs.2021.01.040","article-title":"Identification of natural compounds as potent inhibitors of SARS-CoV-2 main protease using combined docking and molecular dynamics simulations","volume":"28","author":"Jairajpuri","year":"2021","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.bbrep.2024.101913_bib50","doi-asserted-by":"crossref","DOI":"10.1007\/s13205-021-02698-8","article-title":"Exploring the conformational dynamics and flexibility of intrinsically disordered HIV-1 Nef protein using molecular dynamic network approaches","volume":"11","author":"Bhattarai","year":"2021","journal-title":"3 Biotech"},{"key":"10.1016\/j.bbrep.2024.101913_bib51","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","article-title":"RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers","volume":"20","author":"Nichols","year":"2018","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.bbrep.2024.101913_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01519-y","article-title":"Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity","volume":"8","author":"Winters","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrep.2024.101913_bib53","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1158\/2159-8290.CD-18-1220","article-title":"Tissue-specific oncogenic activity of KRASA146T","volume":"9","author":"Poulin","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrep.2024.101913_bib54","article-title":"MEK inhibitors and DA-Raf, a dominant-negative antagonist of the Ras\u2013ERK pathway, prevent the migration and invasion of KRAS-mutant cancer cells","author":"Matsuda","year":"2024","journal-title":"Cytoskeleton"},{"key":"10.1016\/j.bbrep.2024.101913_bib55","article-title":"The SOS1 inhibitor MRTX0902 blocks KRAS activation and demonstrates antitumor activity in cancers dependent on KRAS nucleotide loading","volume":"OF1-OF13","author":"Sudhakar","year":"2024","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.bbrep.2024.101913_bib56","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","article-title":"KRAS G12C inhibition with Sotorasib in advanced solid tumors","volume":"383","author":"Hong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrep.2024.101913_bib57","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrep.2024.101913_bib58","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2174\/0929867330666230330122000","article-title":"First approval of Adagrasib for the treatment of non-small cell lung cancer harboring a KRASG12C mutation","volume":"31","author":"De","year":"2024","journal-title":"Curr. Med. Chem."}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580824002772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580824002772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T20:15:56Z","timestamp":1773864956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580824002772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":58,"alternative-id":["S2405580824002772"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2024.101913","relation":{},"ISSN":["2405-5808"],"issn-type":[{"value":"2405-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elucidating the therapeutic potential of indazole derivative bindarit against K-ras receptor: An in-silico analysis using molecular dynamics exploration","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2024.101913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101913"}}